Abstract: Objective To investigate the effect of Qingqi Huatan Decoction plus budesonide on patients with acute exacerbation of chronic obstructive pulmonary disease. Methods Selected 316 cases of patients with acute exacerbation of chronic obstructive pulmonary disease from September 2020 to December 2022, divided into two groups randomly. The control group was inhaled budesonide by atomization, and the observation group was treated with Qingqi Huatan Decoction. The 1s forced expiratory volume/forced vital capacity (FEV₁/FVC), maximum vital capacity (VCmax), maximum voluntary ventilation volume (MVV) and FEV₁% of the two groups were measured; Airway platform pressure (Pplat), airway resistance (Raw) and airway peak pressure (PIP); Serum interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-α (TNF-α). Results After treatment, the effective rate of the observation group was significantly higher than control group (P<0.05). the expected values of FEV₁/FVC, VCmax, MVV and FEV₁% in the two groups were significantly higher (P<0.05), and the expected values in the observation group were significantly higher than those in the control group (P<0.05). The Pplat, Raw and PIP of the two groups were significantly improved (P<0.05), and the observation group were significantly better than those of the control group (P<0.05). The serum levels of IL-8, MCP-1 and TNF-α in both groups were significantly decreased (P<0.05), the observation group was lower (P<0.05). Conclusion Qingqi Huatan Decoction plus budesonide has a significant effect on acute exacerbation of chronic obstructive pulmonary disease, which can significantly improve the level of respiratory mechanics and lung function, and reduce inflammatory reaction.

Key words: Qingqi Huatan Decoction plus or minus therapy, budesonide, acute exacerbation period, chronic obstructive pulmonary disease